Peptide News Digest

#2-Billion-Peak-Sales

2 stories

Industry · View digest

Takeda Mimrylo Commercial Launch Underway; Rusfertide Second-Day Availability Establishes First-Mover Positioning in Hepcidin Mimetic Peptide Category

Takeda (NYSE: TAK) confirmed Sunday August 30, 2026 that commercial launch of Mimrylo (rusfertide, the first-in-class subcutaneous hepcidin mimetic peptide approved Friday August 28 for erythrocytosis in adults with polycythemia vera) is underway across the U.S., with the product available at specialty pharmacies within 48 hours of FDA approval. The commercial launch approach reflects Takeda's rare-blood-cancer specialty commercial infrastructure built up around Iclusig (ponatinib) for chronic myeloid leukemia and the recent Fruzaqla (fruquintinib) launch in colorectal cancer. Jefferies analyst projections of $2 billion peak sales assume rapid coverage decisions from major U.S. payers by end of 2026 plus European approval on the same clinical dataset in H1 2027. The Mimrylo launch establishes the hepcidin mimetic peptide category and sets a commercial template that Disc Medicine's DISC-0974 (an anti-hemojuvelin antibody targeting hepcidin from a different angle) and Silence Therapeutics' SLN124 (siRNA targeting TMPRSS6, an upstream hepcidin regulator) will need to differentiate against.

Regulatory · View digest

FDA Approves Mimrylo (Rusfertide), the First-in-Class Hepcidin Mimetic Peptide, for Erythrocytosis in Polycythemia Vera

Takeda (NYSE: TAK) and Protagonist Therapeutics (NASDAQ: PTGX) announced Friday August 28, 2026 FDA approval of Mimrylo (rusfertide, a first-in-class subcutaneous synthetic hepcidin mimetic peptide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare BCR-ABL-negative myeloproliferative neoplasm in which uncontrolled red blood cell production drives increased thrombotic risk. Approval was based on the Phase 3 VERIFY trial (n=293) in which 76.9% of patients on rusfertide plus standard of care were phlebotomy-free through Week 32 versus 32.9% on placebo plus standard of care, with statistically significant improvements in hematocrit control and patient-reported fatigue and symptom burden. Adverse events were generally low-grade and included localized injection-site reactions (55.9%), anemia (15.9%), and fatigue (15.2%). Mimrylo will be commercialized by Takeda under the 2024 worldwide license and collaboration agreement with Protagonist and will ship within 48 hours. Jefferies analysts project peak sales potential of $2 billion. The mechanism (mimicking the natural iron-regulator hepcidin to constrain iron availability for erythropoiesis) is the first commercial validation of the hepcidin mimetic peptide class after more than a decade of academic development.